<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5619751</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0184938</article-id><article-id pub-id-type="publisher-id">PONE-D-17-12191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Primates</subject><subj-group><subject>Monkeys</subject><subj-group><subject>Old World monkeys</subject><subj-group><subject>Macaque</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Amniotic Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Amniotic Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Amniotic Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Amniotic Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Primates</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Specimen Preparation and Treatment</subject><subj-group><subject>Staining</subject><subj-group><subject>Cell Staining</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Obstetric Procedures</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Women's Health</subject><subj-group><subject>Maternal Health</subject><subj-group><subject>Pregnancy</subject><subj-group><subject>Chorioamnionitis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Women's Health</subject><subj-group><subject>Obstetrics and Gynecology</subject><subj-group><subject>Pregnancy</subject><subj-group><subject>Chorioamnionitis</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Fetal skin as a pro-inflammatory organ: Evidence from a primate model of chorioamnionitis </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Skin inflammation in the primate fetus</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boonkasidecha</surname><given-names>Suppawat</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kannan</surname><given-names>Paranthaman Senthamarai</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kallapur</surname><given-names>Suhas G.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jobe</surname><given-names>Alan H.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0869-1710</contrib-id><name><surname>Kemp</surname><given-names>Matthew W.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Perinatal Institute, Cincinnati Children’s Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, Ohio, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Division of Neonatology, Department of Pediatrics, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>School of Women’s and Infants’ Health, The University of Western Australia, Perth, Australia</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Center for Perinatal and Neonatal Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kanellopoulos-Langevin</surname><given-names>Colette</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Xavier Bichat Medical School, INSERM-CNRS - Université Paris Diderot, FRANCE</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>matthew.kemp@uwa.edu.au</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>9</issue><elocation-id>e0184938</elocation-id><history><date date-type="received"><day>28</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 Boonkasidecha et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Boonkasidecha et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0184938.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="2" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>Intrauterine infection is a primary cause of preterm birth and fetal injury. </plain></SENT>
<SENT sid="4" pm="."><plain>The pro-inflammatory role of the fetal skin in the setting of intrauterine infection remains poorly characterized. </plain></SENT>
<SENT sid="5" pm="."><plain>Whether or not inflammation of the fetal skin occurs in primates remains unstudied. </plain></SENT>
<SENT sid="6" pm="."><plain>Accordingly, we hypothesized that: i) the fetal primate skin would mount a pro-inflammatory response to preterm birth associated pro-inflammatory agents (lipopolysaccharides from Escherichia coli, live Ureaplasma parvum, interleukin-1β) and; ii) that inhibiting interleukin-1 signaling would decrease the skin inflammatory response. </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="7" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>Rhesus macaques with singleton pregnancies received intraamniotic injections of either sterile saline (control) or one of three pro-inflammatory agonists: E. coli lipopolysaccharides, interluekin-1β or live U. parvum under ultrasound guidance. </plain></SENT>
<SENT sid="9" pm="."><plain>A fourth group of animals received both E. coli lipopolysaccharide and interleukin-1 signaling inhibitor interleukin-1 receptor antagonist (Anakinra) prior to delivery. </plain></SENT>
<SENT sid="10" pm="."><plain>Animals were surgically delivered at approximately 130 days’ gestational age. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="11" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>Intraamniotic lipopolysaccharide caused an inflammatory skin response characterized by increases in interluekin-1β,-6 and -8 mRNA at 16 hours. </plain></SENT>
<SENT sid="13" pm="."><plain>There was a modest inflammatory response to U. parvum, but interleukin-1β alone caused no inflammatory response in the fetal skin. </plain></SENT>
<SENT sid="14" pm="."><plain>Intraamniotic Anakinra treatment of lipopolysaccharide-exposed animals significantly reduced skin inflammation. </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="15" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="16" pm="."><plain>Intraamniotic lipopolysaccharide and U. parvum were associated with modest increases in the expression of inflammatory mediators in primate fetal skin. </plain></SENT>
<SENT sid="17" pm="."><plain>Although administration of Interleukin-1β alone did not elicit an inflammatory response, lipopolysaccharide-driven skin inflammation was decreased following intraamniotic Anakinra therapy. </plain></SENT>
<SENT sid="18" pm="."><plain>These findings provide support for the role of the fetal skin in the development of the fetal inflammatory response. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are presented within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are presented within the paper.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec005"><title><text><SENT sid="19" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="20" pm="."><plain>Preterm birth (delivery before 37 weeks’ gestation) is implicated in more than 1 million perinatal deaths worldwide each year [1]. </plain></SENT>
<SENT sid="21" pm="."><plain>Fetal and intrauterine inflammation cause preterm labor, and the presence of a systemic fetal inflammatory response at delivery is also associated with increased risk of adverse neonatal respiratory and central nervous system outcomes [2]. </plain></SENT>
<SENT sid="22" pm="."><plain>Identifying the gestational tissues responsible for generating intrauterine inflammation is thus an important step in advancing both our understanding of the aetiology of preterm birth and in the development of potential anti-inflammatory interventions. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>A large literature describes the pro-inflammatory responses of the fetal lung and the chorioamnion to pro-inflammatory stimulation. </plain></SENT>
<SENT sid="24" pm="."><plain>However, the role of the fetal skin in driving intrauterine and fetal inflammation is less clear. </plain></SENT>
<SENT sid="25" pm="."><plain>The fetal skin is a large and highly vascularized immunologically competent organ [3, 4] that is continuously exposed to amniotic fluid in utero. </plain></SENT>
<SENT sid="26" pm="."><plain>Amniotic fluid can contain pathogenic microorganisms [5] and proinflammatory mediators associated with preterm labor and delivery including interleukins (IL)-1β, IL-6, IL-8 and tumour necrosis factor (TNF)-α [2, 6, 7]. </plain></SENT>
<SENT sid="27" pm="."><plain>Amniotic contents thus can interact with fetal skin by direct exposure, with the fetal gut epithelium by swallowing, and the fetal lung by fetal breathing and aspiration [8]. </plain></SENT>
<SENT sid="28" pm="."><plain>The skin has innate host defense systems to augment barrier function [9], but little is known about host defense in the skin of the preterm fetus, which in early gestation has minimal cornification and comparatively reduced barrier function [10]. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>Using sheep models of chorioamnionitis induced by the intraamniotic (IA) administration of E.coli lipopolysaccharide (LPS) or live Ureaplasma parvum (UP) we reported that the fetal skin responded with increased inflammatory cells and cytokine expression in the dermis [11–13]. </plain></SENT>
<SENT sid="30" pm="."><plain>With isolation of the oral and nasal epithelium and the fetal lungs and gut, an intra-amniotic exposure to LPS induced a systemic inflammatory response, likely mediated, at least in part, by inflammation in the fetal skin [14]. </plain></SENT>
<SENT sid="31" pm="."><plain>In contrast, exposure of only the fetal gut did not induce a systemic fetal inflammatory response [15]. </plain></SENT>
</text></p><p><text><SENT sid="32" pm="."><plain>There is very little information about how the fetal human or primate skin will respond to chorioamnionitis. </plain></SENT>
<SENT sid="33" pm="."><plain>We recently reported that intra-amniotic injection of LPS or IL-1β given to rhesus macaques with preterm pregnancies caused acute inflammation in the decidua, amniotic fluid, fetal lung and induced fetal inflammatory responses [16]. </plain></SENT>
<SENT sid="34" pm="."><plain>More chronic exposure to live Ureaplasma parvum caused minimal and inconsistent chorioamnionitis in the rhesus [17]. </plain></SENT>
<SENT sid="35" pm="."><plain>In the present report we asked if the fetal primate skin would mount a proinflammatory response to either LPS, live UP and recombinant IL-1β, three clinically relevant proinflammatory mediators associated with prematurity. </plain></SENT>
<SENT sid="36" pm="."><plain>We also sought to determine the importance of IL-1 signalling to a putative skin inflammatory response by the co-administration of LPS and the IL-1 receptor antagonist (IL-1ra) Anakinra. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec006"><title><text><SENT sid="37" pm="."><plain>Materials and methods </plain></SENT>
</text></title><sec id="sec007"><title><text><SENT sid="38" pm="."><plain>Animals </plain></SENT>
</text></title><p><text><SENT sid="39" pm="."><plain>All animal procedures were approved by the Institutional Animal Care and Use committee at the University of California, Davis (18562) with use of approved standard operating procedures for Rhesus macaque (Macaca Mulatta). </plain></SENT>
<SENT sid="40" pm="."><plain>Time mated pregnant females were sedated with ketamine at approximately 125 to 130 days of gestation (term is 165 days) for ultrasound directed IA injections. </plain></SENT>
<SENT sid="41" pm="."><plain>Cesarean section deliveries followed sedation and pre-anesthesia for surgical field preparation and isoflurane anesthesia. </plain></SENT>
<SENT sid="42" pm="."><plain>Briefly, dams were sedated with an intramuscular injection of ketamine (10 mg/kg). </plain></SENT>
<SENT sid="43" pm="."><plain>The dams were then intubated, connected to an electrocardiogram monitor, and anaesthesia was maintained with inhalation isofluorane (1–2% fresh gas flow). </plain></SENT>
<SENT sid="44" pm="."><plain>Intravenous crystalloid solution (0.9% NaCl) was provided at a rate of 10 mL/kg/hour. </plain></SENT>
<SENT sid="45" pm="."><plain>Heart rate, respiratory rate, oxygen saturation, and depth of anaesthesia (jaw tone, corneal and palpebral reflexes, limb withdrawal reflex) were constantly monitored during the procedure. </plain></SENT>
<SENT sid="46" pm="."><plain>The fetus was removed in cull for recovery of gestational tissues and amniotic fluid, and euthanized with intravenous pentobarbital. </plain></SENT>
<SENT sid="47" pm="."><plain>The dam then received an intramuscular injection of atropine (0.04 mg/kg). </plain></SENT>
<SENT sid="48" pm="."><plain>Anaesthesia was withdrawn at the end of the procedure and dams were recovered with supplemental oxygen provided until airway control was regained. </plain></SENT>
<SENT sid="49" pm="."><plain>The dam’s appetite, hydration, stool quality, pain score, and incision site appearance was observed and recorded postoperatively for at least seven days. </plain></SENT>
<SENT sid="50" pm="."><plain>Intramuscular oxymorphone (0.15 mg/kg; administered between one and three times each day) was provided under veterinary direction based on clinical need. </plain></SENT>
</text></p><p><text><SENT sid="51" pm="."><plain>The treatments were as follows: </plain></SENT>
</text></p><list list-type="order"><list-item><p><text><SENT sid="52" pm="."><plain>LPS: LPS (1mg, E. coli O55:B5, Sigma Aldrich, Saint Louis, MO) in 1 mL of sterile saline solution was given by ultrasound-guided IA injection. </plain></SENT>
<SENT sid="53" pm="."><plain>After either 16 or 48 hours, fetuses were surgically delivered for fetal tissue collection; </plain></SENT>
</text></p></list-item><list-item><p><text><SENT sid="54" pm="."><plain>Ureaplasma: Rhesus macaque dams were injected intra-amniotically with 107 CFU Ureaplasma parvum (UP) serovar 1[17] under ultrasound gudiance. </plain></SENT>
<SENT sid="55" pm="."><plain>Fetuses were delivered surgically either 3 or 7 days later; </plain></SENT>
</text></p></list-item><list-item><p><text><SENT sid="56" pm="."><plain>IL-1β: Rhesus macaque dams received 10 μg human recombinant IL-1β (Peprotech, Rockyhill, NJ) in 1 ml sterile saline or 1 ml sterile saline by ultrasound guided intra-amniotic injection [16] and were delivered either 1 or 3 days later; and </plain></SENT>
</text></p></list-item><list-item><p><text><SENT sid="57" pm="."><plain>LPS and IL-1ra: LPS (1mg, E. coli O55:B5, Sigma Aldrich, Saint Louis, MO) in 1 mL of sterile saline solution was given by ultrasound-guided IA injection. </plain></SENT>
<SENT sid="58" pm="."><plain>50mg IA and 100mg subcutaneous (SC) IL-1ra (Anakinra Sobi, Stockholm, Sweden) was given to pregnant monkeys at 1 and 3 hours, respectively before IA LPS administration. </plain></SENT>
<SENT sid="59" pm="."><plain>Fetuses were surgically delivered for fetal tissue collection after either 16 or 48 hours. </plain></SENT>
</text></p></list-item></list><p><text><SENT sid="60" pm="."><plain>The variation in time to delivery between groups reflects the difference in the nature of the anticipated inflammatory response generated by different agonists, and to assess inflammatory responses at acute and also longer-term time points. </plain></SENT>
<SENT sid="61" pm="."><plain>Animals that were delivered 48 hours after IA LPS received a second IA + SC IL-1ra treatment, administered 24 hours after the first treatment. </plain></SENT>
<SENT sid="62" pm="."><plain>Matched saline controls were established for each of the four treatment groups. </plain></SENT>
<SENT sid="63" pm="."><plain>Samples of skin from the groin were fixed in 10% formalin for histological analysis, or snap frozen in liquid nitrogen for mRNA studies. </plain></SENT>
</text></p></sec><sec id="sec008"><title><text><SENT sid="64" pm="."><plain>mRNA quantitation </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>Total RNA was isolated from frozen skin samples by homogenization with TRIzol (Invitrogen, Carlsbad, CA) and column purification with RNeasy Universal Mini Kits (Qiagen, Valencia, CA) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="66" pm="."><plain>Reverse transcription was performed using Verso cDNA kit (Thermo Scientific, Waltham, MA). </plain></SENT>
<SENT sid="67" pm="."><plain>The relative expression of IL-1β, TNF-α, IL-6, IL-8, IL-10, IL-1α, IL-17α and monocyte chemoattractant protein 1 (MCP-1) was determined by rt-PCR using the cDNA template and rhesus macaque-specific Taqman probes and primers (Applied Biosystems, Foster City, CA). </plain></SENT>
<SENT sid="68" pm="."><plain>The mRNA expression for each gene was normalized to the mRNA for the 18s ribosomal protein as the endogenous control and a sample from the control group was used as a calibrator. </plain></SENT>
<SENT sid="69" pm="."><plain>Data are expressed as fold increase over the mean control value. </plain></SENT>
<SENT sid="70" pm="."><plain>Probe and primer set details are presented in Table 1. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0184938.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0184938.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="71" pm="."><plain>Summary of PCR sets. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0184938.t001g" xlink:href="pone.0184938.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>TaqMan Probe </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>Assay ID(Applied Biosystems) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>Entrez Gene ID </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>IL-1β </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.thermofisher.com/taqman-gene-expression/product/Rh02621711_m1?CID=&amp;ICID=&amp;keyword=Rh02621711_m1&amp;configurator=false&amp;subtype=ge_all">Rh02621711_m1</ext-link> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene?term=704701">704701</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>IL-6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/taqman-gene-expression/product/Rh02789322_m1?CID=&amp;ICID=&amp;keyword=rh02789322_m1&amp;configurator=false&amp;subtype=">Rh02789322_m1</ext-link> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene?term=705819">705819</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>IL-8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/taqman-gene-expression/product/Rh02789781_m1?CID=&amp;ICID=&amp;keyword=rh02789781_m1&amp;configurator=false&amp;subtype=">Rh02789781_m1</ext-link> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene?term=613028">613028</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>TNF </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/taqman-gene-expression/product/Rh02789783_m1?CID=&amp;ICID=&amp;keyword=rh02789783_m1&amp;configurator=false&amp;subtype=">Rh02789783_m1</ext-link> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene?term=715467">715467</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>IL-10 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/taqman-gene-expression/product/Rh00961619_m1?CID=&amp;ICID=&amp;keyword=rh00961619_m1&amp;configurator=false&amp;subtype=">Rh00961619_m1</ext-link> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene?term=694931">694931</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>IL-1α </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>Rh02789770_m1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene?term=700193">700193</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>IL-17A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/taqman-gene-expression/product/Rh02621750_m1?CID=&amp;ICID=&amp;keyword=rh02621750_m1&amp;configurator=false&amp;subtype=">Rh02621750_m1</ext-link> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene?term=708123">708123</ext-link> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>MCP-1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/taqman-gene-expression/product/Rh02621753_m1?CID=&amp;ICID=&amp;keyword=rh02621753_m1&amp;configurator=false&amp;subtype=">Rh02621753_m1</ext-link> </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene?term=574138">574138</ext-link> </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="sec009"><title><text><SENT sid="99" pm="."><plain>Immunohistochemistry </plain></SENT>
</text></title><p><text><SENT sid="100" pm="."><plain>Immunohistochemistry was performed with 5 μm thick sections of formalin fixed tissues. </plain></SENT>
<SENT sid="101" pm="."><plain>Sections were de-paraffinized and rehydrated before microwave-assisted antigen retrieval in citric acid buffer at pH 6.0. </plain></SENT>
<SENT sid="102" pm="."><plain>Endogenous peroxidase activity was reduced with CH3OH/H2O2 treatment and the tissue was blocked with 4% normal goat serum in PBS. </plain></SENT>
<SENT sid="103" pm="."><plain>Sections were incubated overnight at 4°C with the primary antibody diluted in 4% serum in PBS. </plain></SENT>
<SENT sid="104" pm="."><plain>The following primary antibodies were used: anti-myeloperoxidase (MPO, Cell Marque 289A-75, cat. # 1404306A, dilution 1:200), anti-CD3 (Dako Cytomation, A0452 cat. # 20024875, dilution, 1:100), anti-CD 68 (Biosciences Pharmingen, M0814, cat. # 24648, dilution 1:200), anti-IL-8 (BD Bioscience, cat. # 550419, dilution, 1:100), anti-IL-6 (Lifespan Bioscience, Inc. </plain></SENT>
<SENT sid="105" pm="."><plain>LS-B7482 cat. # 37847, dilution, 1:400) and Anti-Pancytokeratin (Santa Cruz Biotechnology, SC-81714, cat. # B1015, dilution, 1:2500), with dilutions made in 4% normal goat serum. </plain></SENT>
<SENT sid="106" pm="."><plain>Sections were then washed and incubated with the appropriate species-specific secondary antibody diluted 1:200 in 4% serum for 2 hours at room temperature. </plain></SENT>
<SENT sid="107" pm="."><plain>After further washing, antigen:antibody complexes were visualized using a Vectastain ABC peroxidase kit (Vector Laboratories Inc., Burlingame, CA). </plain></SENT>
<SENT sid="108" pm="."><plain>Antigen detection was enhanced with nickel-diaminobenzidine, followed by incubation with Tris-1-cobalt. </plain></SENT>
<SENT sid="109" pm="."><plain>Slides were counterstained with Nuclear Fast Red for photomicroscopy. </plain></SENT>
<SENT sid="110" pm="."><plain>Blinded digital images of the fetal rhesus skin (5 non-overlapping, random fields per animal) were quantified for the total number of inflammatory cells, and immunostaining for IL-6, IL-8, neutrophil (MPO), monocyte/macrophage (CD68), and T-cells (CD3). </plain></SENT>
<SENT sid="111" pm="."><plain>Pancytokeratin staining intensity was also quantified by a blinded investigator, based on color threshold and expressed as percentage of intense, moderate and no staining area relative to total area. </plain></SENT>
</text></p></sec><sec id="sec010"><title><text><SENT sid="112" pm="."><plain>Cell counting </plain></SENT>
</text></title><p><text><SENT sid="113" pm="."><plain>Sections stained for IL-6, IL-8, CD3 (T-cells), CD68 and MPO were counted for number of positive cells in ten randomly-selected fields per animal on photomicrographs (40x objective magnification) from the epidermal to dermal layers by an investigator blinded to treatment groups. </plain></SENT>
<SENT sid="114" pm="."><plain>A similar strategy was used to determine the percentage of cells positively stained for pancytokeratin (1:2,500), to determine both the number and the percentage cells with either intense, moderate or no staining. </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="115" pm="."><plain>Statistical analyses </plain></SENT>
</text></title><p><text><SENT sid="116" pm="."><plain>GraphPad Prism (GraphPad Software 5.Ink, La Jolla, CA) was used to graph and analyze data for statistical significance. </plain></SENT>
<SENT sid="117" pm="."><plain>Data are presented as means ± SEM (standard error of the mean). </plain></SENT>
<SENT sid="118" pm="."><plain>Data were tested for normality and variance; statistical differences between groups were analyzed using Mann–Whitney U tests. </plain></SENT>
<SENT sid="119" pm="."><plain>Values of p&lt;0.05 were considered significant. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec012"><title><text><SENT sid="120" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec013"><title><text><SENT sid="121" pm="."><plain>Animals </plain></SENT>
</text></title><p><text><SENT sid="122" pm="."><plain>There was no preterm labor or evident abnormalities in animals from either the four treatment groups or matched saline controls. </plain></SENT>
<SENT sid="123" pm="."><plain>Gestational ages at birth and birth weights were similar among the animals (Table 2). </plain></SENT>
<SENT sid="124" pm="."><plain>Mean fetal weights at tissue collection were not different between groups. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0184938.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0184938.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="125" pm="."><plain>Treatment groups Intra-amniotic injections of LPS, IL-1β, and Ureaplasma parvum (UP) or saline were performed in multiparous macaques of similar weight and age. </plain></SENT>
</text></title><p><text><SENT sid="126" pm="."><plain>Separate animals were used for controls for each treatment group. </plain></SENT>
<SENT sid="127" pm="."><plain>Mean fetal weights at tissue collection were not different between groups. </plain></SENT>
</text></p></caption><alternatives><graphic id="pone.0184938.t002g" xlink:href="pone.0184938.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>Treatment </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>N </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>Gestational age (days) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>Birth Weight(gm) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>Sex(M:F) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>LPS and IL-1ra treatment </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>Saline Control </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>13 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>132±0.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>337±8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>6:7 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>LPS-16h </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>132±0.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>326±12 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>6:5 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>LPS-48h </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>132±0.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>320±10 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>1:7 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>LPS and IL-1ra-16h </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>132±1.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>354±14 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>3:3 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>LPS and IL-1ra-48h </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>128±0.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>315±9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>3:0 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>IL-1β treatment </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Saline Control </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>131±1.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>310±9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>0:5 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>IL-1β- 1d </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>130±0.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>341±13 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>3:2 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>IL-1β- 3d </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>129±0.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>346±38 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>1:4 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>UP treatment </plain></SENT>
</text></td><td align="center" colspan="2" rowspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>Saline Control </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>132±0.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>343±4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>3:2 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>UP-3d </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>130±1.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>348±19 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>2:3 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>UP-7d </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>130±0.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>341±8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>2:3 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="sec014"><title><text><SENT sid="191" pm="."><plain>IA LPS, UP but not IL-1β increase cytokine expression in the fetal rhesus skin </plain></SENT>
</text></title><p><text><SENT sid="192" pm="."><plain>IL-1β, IL-6 and IL-8 mRNA significantly increased 16 hours after IA LPS (p&lt;0.05). </plain></SENT>
<SENT sid="193" pm="."><plain>Only IL-8 mRNA remained significantly elevated 48h after LPS exposure (Fig 1, panels a-c). </plain></SENT>
<SENT sid="194" pm="."><plain>The cytokines TNF-α, IL-1α, and MCP-1 did not change with LPS exposure, and IL-10 was undetectable in association with LPS exposure. </plain></SENT>
<SENT sid="195" pm="."><plain>In the UP treatment group, IL-1β mRNA was significantly increased by 25-fold at 3 days and IL-6 mRNA increased by 5-fold at 7 days after IA UP (p&lt;0.05, Fig 1, panels a and b). </plain></SENT>
<SENT sid="196" pm="."><plain>In contrast to LPS exposure, TNF-α increased significantly 15 fold at 3 days and 9 fold at 7 days, but IL-10, IL-1α, and MCP-1 did not change with UP exposure (Table 3). </plain></SENT>
<SENT sid="197" pm="."><plain>IL-1β treatment did not significantly increase the mRNA expression of any of the cytokines or chemokines measured at either time point. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0184938.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0184938.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="198" pm="."><plain>Cytokine PCR Analysis. </plain></SENT>
</text></title><p><text><SENT sid="199" pm="."><plain>Quantitative PCR analysis of cytokines in fetal rhesus macaque skin following intra-amniotic exposure with LPS, IL-1β or UP and for different times of exposure (Panel a, b and c). </plain></SENT>
<SENT sid="200" pm="."><plain>Cytokine expression for LPS and LPS plus IL-1ra exposure groups (Panel d, e and f). </plain></SENT>
<SENT sid="201" pm="."><plain>Graphs represent mean mRNA fold change ± SD. *indicates a significant increase in transcript expression relative to untreated control group normalized to a value for 1.0. ɸ indicates a significant decrease in transcript expression relative to LPS at 16 hours. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0184938.g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone.0184938.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0184938.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="202" pm="."><plain>Summary of cytokine / chemokine mRNA expression. </plain></SENT>
</text></title><p><text><SENT sid="203" pm="."><plain>Data are mean ± SD; *p = 0.05. </plain></SENT>
<SENT sid="204" pm="."><plain>Cells without data represent transcript levels below limit of detection. </plain></SENT>
</text></p></caption><alternatives><graphic id="pone.0184938.t003g" xlink:href="pone.0184938.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>TNF </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>IL-10 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>IL-1α </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>MCP-1 </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>Control </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>1.0±0.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>1.0±1.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>1.0 ±0.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>1.0±0.9 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>LPS 16h </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>1.3±0.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>2.5±3.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>1.4±0.8 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>LPS+IL-1RA 16h </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>1.2±0.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>1.8±1.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>1.8±0.6 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>LPS 48h </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>3.1±5.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>1.3±0.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>1.0±0.8 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>LPS+IL-1RA 48h </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>3.3±3.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>3.7±3.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>1.2±0.6 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>IL-1B 1d </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>1.7±1.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>2.3±2.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>1.7±1.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>0.7±0.3 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>IL-1B 3d </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>1.1±0.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>0.6±0.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>0.7±0.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>0.3±0.1 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>UP 3d </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>15.0±29.6* </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>1.4±1.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>2.4±2.6 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>UP 7d </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>9.0±8.9* </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>- </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>1.2±0.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>2.7±2.1 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="sec015"><title><text><SENT sid="254" pm="."><plain>IL-1ra decreased IL-1β and IL-8 mRNA expression in LPS exposed fetal rhesus skin </plain></SENT>
</text></title><p><text><SENT sid="255" pm="."><plain>In the LPS + IL-1ra treatment group, there were statistically significant decreases in IL-1β and IL-8 mRNA expression at 16 hours (p&lt;0.05, Fig 1, panels d and f) relative to LPS-treatment only. </plain></SENT>
</text></p></sec><sec id="sec016"><title><text><SENT sid="256" pm="."><plain>IA LPS and the impact of IA IL-1ra on inflammatory mediators </plain></SENT>
</text></title><p><text><SENT sid="257" pm="."><plain>We performed immunohistochemistry (IHC) for IL-6, IL-8, CD3, CD68, MPO and pancytokeratin. </plain></SENT>
<SENT sid="258" pm="."><plain>The number of cells positively stained for IL-6 and pancytokeratin increased significantly 16 hours after IA LPS (p&lt;0.05, Figs 2 and 3). </plain></SENT>
<SENT sid="259" pm="."><plain>We did not identify changes in the other markers assessed. </plain></SENT>
<SENT sid="260" pm="."><plain>The administration of IL-1ra significantly decreased the number of IL-6 positive cells (p&lt;0.05, Fig 2). </plain></SENT>
<SENT sid="261" pm="."><plain>There was a significant increase in the percentage of intensely positive pancytokeratin stained cells for the LPS group at 16 hours relative to the untreated control group. </plain></SENT>
<SENT sid="262" pm="."><plain>At 16 hours, there was significant decrease in the percent of intense positive cell after IA IL-1ra administration (p&lt;0.05, Fig 3). </plain></SENT>
<SENT sid="263" pm="."><plain>There was no difference in moderate staining of pancytokeratin IHC between groups. </plain></SENT>
<SENT sid="264" pm="."><plain>We did not observe infiltrating neutrophils (MPO), leukocytes (CD3+) or infiltrating macrophages (CD68+) in fetal skin after IA LPS treatment. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0184938.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0184938.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="265" pm="."><plain>IL-6 expression. </plain></SENT>
</text></title><p><text><SENT sid="266" pm="."><plain>Representative photomicrographs for IL-6 (1:400) immunohistochemical staining of fetal skin. </plain></SENT>
<SENT sid="267" pm="."><plain>(A) control; (B) LPS at 16 h; (C) LPS and IL-1ra at 16 h exposure. </plain></SENT>
<SENT sid="268" pm="."><plain>(D) The number of positive cells (arrow), that were counted between groups. </plain></SENT>
<SENT sid="269" pm="."><plain>(magnification bar represents 20 μm). *indicates a significant increase in the number of positive cells relative to the untreated control. ɸ indicates a significant decrease in number of positive cells relative to LPS. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0184938.g002"/></fig></SecTag><SecTag type="FIG"><fig id="pone.0184938.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0184938.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="270" pm="."><plain>Pancytokeratin expression. </plain></SENT>
</text></title><p><text><SENT sid="271" pm="."><plain>Representative photomicrographs for pancytokeratin (1:2500) immunohistochemical staining of fetal skin. </plain></SENT>
<SENT sid="272" pm="."><plain>(A) control; (B) LPS at 16 h; (C) LPS and IL-1ra at 16 h exposure. </plain></SENT>
<SENT sid="273" pm="."><plain>(D) Graph shows the comparison between groups in the percent of positive cells of different intensity stain; intense (arrow), moderate and no stain (magnification bar represents 20 μm). *indicates a significant difference in the percent of positive cell between LPS at 16 hours and untreated control group. ɸ indicates a significant difference in the percent of positive cell between LPS group and LPS plus IL-1ra group at 16 hours. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0184938.g003"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec017"><title><text><SENT sid="274" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="275" pm="."><plain>We demonstrate that the fetal rhesus skin is capable of generating an inflammatory response in utero, in response to direct stimulation by both LPS and UP. </plain></SENT>
<SENT sid="276" pm="."><plain>In LPS-exposed animals, we show that this response involves increased expression of mRNA transcripts for preterm birth-associated proinflammatory cytokines IL-1β, IL-6, and IL-8, and increased staining for IL-6 and pancytokeratin in the skin. </plain></SENT>
<SENT sid="277" pm="."><plain>This observation is consistent with previous reports of increased expression of cytokeratin following stimulation of keratinocytes with pro-inflammatory cytokines [18]. </plain></SENT>
<SENT sid="278" pm="."><plain>IA UP-treatment resulted in increased IL-1β mRNA expression at 3d post-treatment and increased IL-6 expression at 7d post-treatment. </plain></SENT>
<SENT sid="279" pm="."><plain>Although these studies were not designed to accurately determine the ontogeny of skin responses to inflammatory agonist, it is apparent that the skin is able to rapidly mount an inflammatory response to microbial agonist and, that in the case of UP, this response persists for an extended period. </plain></SENT>
<SENT sid="280" pm="."><plain>In our experimental system it is not possible to isolate the impact of systemic vs direct agonist inflammatory stimulation on the fetal skin. </plain></SENT>
</text></p><p><text><SENT sid="281" pm="."><plain>IA administration of IL-1β alone was not associated with pro-inflammatory changes in the fetal skin. </plain></SENT>
<SENT sid="282" pm="."><plain>However, the co-administration of IL-1ra with LPS was associated with significant reductions in IL-1β and IL-8 transcript expression, in the number of IL-6 positive cells in the dermis, and in the intensity pancytokeratin staining relative to LPS-treatment only. </plain></SENT>
<SENT sid="283" pm="."><plain>Taken together, these results demonstrate that both LPS and UP can induce fetal skin inflammation, and, given that LPS-driven inflammatory responses are partially blocked with IA IL-1ra therapy, that IL-1 signaling likely plays an important role in skin inflammation in utero. </plain></SENT>
</text></p><p><text><SENT sid="284" pm="."><plain>Infection of amniotic fluid results in the production of proinflammatory cytokines and chemokines [19, 20]. </plain></SENT>
<SENT sid="285" pm="."><plain>The fetal skin, which has a large surface area, is entirely exposed to the amniotic fluid containing any invading microorganisms and proinflammatory agonists. </plain></SENT>
<SENT sid="286" pm="."><plain>Important questions that remain unanswered are the relative importance of maternal or fetal inflammation, and which tissues (chorioamnion, placenta, fetal lung or fetal skin) are primarily responsible for initiating the fetal inflammatory responses. </plain></SENT>
</text></p><p><text><SENT sid="287" pm="."><plain>We suggest that the developing fetal skin may contribute to the acute fetal inflammatory response (FIRS), which is associated with preterm birth and adverse neonatal outcomes. </plain></SENT>
<SENT sid="288" pm="."><plain>Even a limited inflammatory fetal skin response could have systemic effects on the fetus due to a large surface area and the high degree of vascularization. </plain></SENT>
<SENT sid="289" pm="."><plain>We previously showed in fetal sheep that chorioamnionitis caused by the intra-amniotic injection of LPS resulted in inflammation, particularly of the fetal lung, gut, skin, and chorioamnion [13, 21, 22]. </plain></SENT>
<SENT sid="290" pm="."><plain>IL-1 was central to this inflammation as blockade of IL-1 signaling in the amniotic compartment with the same recombinant IL-1 receptor antagonist (IL-1ra) largely inhibited the fetal lung and systemic inflammation caused by intra-amniotic E. coli LPS [20]. </plain></SENT>
<SENT sid="291" pm="."><plain>The skin inflammatory response to UP were modest but the evaluation was 3 and 7 days after IA injection of organisms. </plain></SENT>
<SENT sid="292" pm="."><plain>We anticipate that there would be a longer interval from IA injection to an inflammation for UP than LPS. </plain></SENT>
</text></p><p><text><SENT sid="293" pm="."><plain>The proinflammatory cytokines IL-1β and TNF-α are considered primary mediators of septic shock and are also associated with infection-induced preterm delivery [16]. </plain></SENT>
<SENT sid="294" pm="."><plain>The robust expression of IL-1 β by the primate fetal skin in response to IA LPS stimulation may be of significance, given the association of these cytokines with infection-associated preterm labor. </plain></SENT>
<SENT sid="295" pm="."><plain>Increases in IL-6 expression are frequently identified in association with preterm birth. </plain></SENT>
<SENT sid="296" pm="."><plain>IL-6 is a marker of systemic fetal inflammatory response syndrome (cord blood IL-6 &gt;11 pg/mL) [2, 6, 19]. </plain></SENT>
<SENT sid="297" pm="."><plain>In the present study, IL-6 transcript expression in the fetal skin was increased significantly only after 16 hours of LPS stimulation, but remained elevated 7d after UP exposure. </plain></SENT>
<SENT sid="298" pm="."><plain>IL-8 is a potent chemotactant and neutrophil activating factor which is part of the response elicited in the host against microbial invasion. </plain></SENT>
</text></p><p><text><SENT sid="299" pm="."><plain>IL-8 also can recruit neutrophils to the fetal membranes and the placenta during the development of an intrauterine infection. </plain></SENT>
<SENT sid="300" pm="."><plain>There was no significant change in IL-8 protein expression in response to UP administration at either 3d or 7d. </plain></SENT>
<SENT sid="301" pm="."><plain>Although IL-8 transcript expression in the fetal skin was increased significantly both 16 and 48 hours post-LPS stimulation, we did not observe infiltrating neutrophils (MPO), leukocytes (CD3+) or infiltrating macrophages (CD68+) in fetal rhesus skin as we anticipated. </plain></SENT>
</text></p><p><text><SENT sid="302" pm="."><plain>A possible explanation for these findings may be the structural immaturity of the fetal skin which may allow immunocytes to move from the skin to the amniotic fluid. </plain></SENT>
<SENT sid="303" pm="."><plain>Previous studies have suggested that fetal immunocytes (specifically, neutrophils, lymphocytes and monocytes) are recruited into the amniotic fluid [22]. </plain></SENT>
<SENT sid="304" pm="."><plain>After IA LPS administration, immunocytes isolated from the amniotic fluid expressed proinflammatory cytokine mRNA for IL-8 at 72 hours and 7 days while no cytokine mRNA can be detected in the chorioamnion, lung, or spleen after 72 hours [22]. </plain></SENT>
<SENT sid="305" pm="."><plain>The permeable nature of the developing fetal rhesus skin at early gestation may be permissive for the transepidermal passage of cytokines and chemokines from the fetus into the amniotic fluid [22]. </plain></SENT>
</text></p><p><text><SENT sid="306" pm="."><plain>In the present study, an injection of IL-1β sufficient to induce chorioamnionitis and fetal inflammatory response [16] did not cause skin inflammation in the non-human primate. </plain></SENT>
<SENT sid="307" pm="."><plain>In a related unpublished observation, IA IL-1β also did not cause skin inflammation in sheep (M. </plain></SENT>
<SENT sid="308" pm="."><plain>Kemp, Personal Communication). </plain></SENT>
<SENT sid="309" pm="."><plain>This observation is of interest, given the importance of IL-1 signaling to skin inflammation, and the robust response seen in the macaque fetal lung and chorioamnion in response to IL-1β stimulation. </plain></SENT>
<SENT sid="310" pm="."><plain>IL-1 is well established as a critical mediator of skin inflammation, with both IL-1α and IL-1β acting via IL-1 receptor 1. </plain></SENT>
<SENT sid="311" pm="."><plain>Enk and colleagues, for example, have proposed that IL-1β produced by dendritic cells may be critical to the induction of skin immune responses[23]. </plain></SENT>
<SENT sid="312" pm="."><plain>Dysregulation of the IL-1α: IL-1Ra ratio has been implicated in a range of inflammatory skin diseases including psoriasis and contact dermatitis [24]. </plain></SENT>
</text></p><p><text><SENT sid="313" pm="."><plain>Biologically active 31 kDa IL-1α is the predominant form expressed by epithelial cells, including keratinocytes. </plain></SENT>
<SENT sid="314" pm="."><plain>In contrast, biologically active IL-1β is generated by cleavage of the 31 kDa inactive form by stimulated Langerhans cells, monocytes and macrophages. </plain></SENT>
<SENT sid="315" pm="."><plain>Although keratinocytes also generate the biologically inactive 31kDa IL-1β precursor, they largely lack the enzyme necessary to complete significant post-translational generation of the mature 17 kDa protein [25]. </plain></SENT>
</text></p><p><text><SENT sid="316" pm="."><plain>It is tempting to speculate as to why 10 ug of IA IL-1β failed to elicit skin inflammation in the macaque fetus, despite being associated with pulmonary inflammation and chorioamnionitis. </plain></SENT>
<SENT sid="317" pm="."><plain>Firstly, it is possible that there was insufficient IL1R available in the fetal skin to drive a detectable inflammatory response to IL-1β stimulation. </plain></SENT>
<SENT sid="318" pm="."><plain>Using newborn human foreskin samples, Groves and colleagues demonstrated that in contrast to adult human skin (which demonstrates robust basal and apical epidermal IL-1R staining [26]) untreated tissues expressed very few IL-1R (either type 1 or 2), although significant and rapid increases in the expression of the type-II (inhibitory) IL-1R could be induced by tissue stimulation with interferon-ɣ, or by overnight incubation at 37°C [27]. </plain></SENT>
<SENT sid="319" pm="."><plain>In contrast, Toll-like receptors (including Toll-like receptor 4, which is strongly agonized by LPS) are expressed in skin from an early gestational age, likely facilitating the LPS-driven response identified in the present report[28]. </plain></SENT>
<SENT sid="320" pm="."><plain>However, against this hypothesis is our observation that IL-1Ra was able to antagonize LPS-driven inflammation, which itself requires the binding of IL-1Ra to type I IL-1R. </plain></SENT>
</text></p><p><text><SENT sid="321" pm="."><plain>Secondly, it is possible that the dose of IL-1β administered was insufficient to overcome inhibition of IL-1R1 signaling by endogenously expressed IL1Ra, although given the high ration of IL-1Ra: IL1 required to inhibit productive signaling (ranging between 10:1 and 100:1 [24]), this explanation also seems unlikely. </plain></SENT>
<SENT sid="322" pm="."><plain>Thirdly, it is possible that the magnitude of inflammatory response generated by IL-1β stimulation were too small to be identified statistically with the group sizes used in our study. </plain></SENT>
<SENT sid="323" pm="."><plain>Lastly, unlike in the fetal lung, it is possible that IL-1β-driven responses in the skin are acute, modest, and resolve within 24h. </plain></SENT>
</text></p><p><text><SENT sid="324" pm="."><plain>There are a number of clinical correlations of this study. </plain></SENT>
<SENT sid="325" pm="."><plain>In chorioamnionitis-induced fetal inflammatory response, the fetal skin may contribute to the inflammation in the amniotic fluid and systemically. </plain></SENT>
<SENT sid="326" pm="."><plain>Furthermore, skin inflammation could further compromise the already poor barrier function of the fetus or decrease the permeability by the increased cornification. </plain></SENT>
<SENT sid="327" pm="."><plain>Infants exposed to chorioamnionitis could have an increased predisposition to nosocomial infection from alterations in skin barrier function. </plain></SENT>
<SENT sid="328" pm="."><plain>IA IL-1ra therapy can block the inflammatory responses in primate fetal skin and FIRS from LPS, the receptor blockers may both block preterm delivery and fetal injury. </plain></SENT>
</text></p><p><text><SENT sid="329" pm="."><plain>In conclusion, the primate fetal skin can mount an inflammatory response to in utero inflammation, although this response is modest and appears to lack an immunocyte response, at least acutely. </plain></SENT>
<SENT sid="330" pm="."><plain>However, given the size, degree of vascularization, and direct exposure to the amniotic fluid, the primate fetal skin may be an important source of the both fetal inflammation and pro-inflammatory mediators that could signal the chorioamnion, cervix, and uterus to ultimately induce preterm labor. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="331" pm="."><plain>The authors wish to thank Manuel Alvarez for the technical support and assistance in performing skin sections. </plain></SENT>
<SENT sid="332" pm="."><plain>The authors are grateful to the staff of California National Primate Research Centre (University of California, Davis) for their expert assistance with animal studies. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>IA</term><def><p>Intraamniotic</p></def></def-item><def-item><term>LPS</term><def><p>lipopolysaccharides</p></def></def-item><def-item><term>UP</term><def><p><italic>Ureaplasma</italic>
<italic>parvum</italic></p></def></def-item><def-item><term>IL</term><def><p>Interleukin</p></def></def-item><def-item><term>TNF</term><def><p>Tumour necrosis factor</p></def></def-item><def-item><term>CFU</term><def><p>Colony forming unit</p></def></def-item><def-item><term>CCL2</term><def><p>Chemokine ligand 2</p></def></def-item><def-item><term>ELISA</term><def><p>Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>MCP-1</term><def><p>Monocyte Chemoattractant Protein-1</p></def></def-item><def-item><term>MPO</term><def><p>Myeloperoxidase</p></def></def-item><def-item><term>PBS</term><def><p>Phosphate buffer saline</p></def></def-item></def-list></glossary></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0184938.ref001"><text><SENT sid="333" pm="."><plain>1March of Dimes P, Save the Children, WHO. Born Too Soon: The Gobal Action Report on Preterm Birth Geneva: World Health Organisation, 2012. </plain></SENT>
</text></ref><ref id="pone.0184938.ref002"><text><SENT sid="334" pm="."><plain>2RomeroR, DeySK, FisherSJ. Preterm labor: One syndrome, many causes. Science. 2014;345(6198):760–5. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1251816">10.1126/science.1251816</ext-link> <?supplied-pmid 25124429?>25124429 </plain></SENT>
</text></ref><ref id="pone.0184938.ref003"><text><SENT sid="335" pm="."><plain>3MillerLS. Toll-like receptors in skin. Advances in dermatology. 2008;24:71–87. </plain></SENT>
<SENT sid="336" pm="."><plain>Epub 2008/01/01. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.yadr.2008.09.004">10.1016/j.yadr.2008.09.004</ext-link> ; PubMed Central PMCID: PMCPmc2633625.<?supplied-pmid 19256306?>19256306 </plain></SENT>
</text></ref><ref id="pone.0184938.ref004"><text><SENT sid="337" pm="."><plain>4SugitaK, KabashimaK, AtarashiK, ShimauchiT, KobayashiM, TokuraY. Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin. Clinical and experimental immunology. 2007;147(1):176–83. </plain></SENT>
<SENT sid="338" pm="."><plain>Epub 2006/12/21. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-2249.2006.03258.x">10.1111/j.1365-2249.2006.03258.x</ext-link> ; PubMed Central PMCID: PMCPmc1810440.<?supplied-pmid 17177977?>17177977 </plain></SENT>
</text></ref><ref id="pone.0184938.ref005"><text><SENT sid="339" pm="."><plain>5CombsCA, GravettM, GariteTJ, HickokDE, LapidusJ, PorrecoR, et al Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. American journal of obstetrics and gynecology. 2014;210(2):125e1-.e15. </plain></SENT>
<SENT sid="340" pm="."><plain>Epub 2013/11/28. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajog.2013.11.032">10.1016/j.ajog.2013.11.032</ext-link> .<?supplied-pmid 24274987?>24274987 </plain></SENT>
</text></ref><ref id="pone.0184938.ref006"><text><SENT sid="341" pm="."><plain>6RomeroR, EspinozaJ, KusanovicJP, GotschF, HassanS, ErezO, et al The preterm parturition syndrome. BJOG: an international journal of obstetrics and gynaecology. 2006;113 Suppl 3:17–42. </plain></SENT>
<SENT sid="342" pm="."><plain>Epub 2007/01/09. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1471-0528.2006.01120.x">10.1111/j.1471-0528.2006.01120.x</ext-link> .<?supplied-pmid 17206962?>17206962 </plain></SENT>
</text></ref><ref id="pone.0184938.ref007"><text><SENT sid="343" pm="."><plain>7ThaxtonJE, NeversTA, SharmaS. TLR-mediated preterm birth in response to pathogenic agents. Infectious diseases in obstetrics and gynecology. 2010;2010 Epub 2010/09/10. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2010/378472">10.1155/2010/378472</ext-link> ; PubMed Central PMCID: PMCPmc2933901.<?supplied-pmid 20827416?>20827416 </plain></SENT>
</text></ref><ref id="pone.0184938.ref008"><text><SENT sid="344" pm="."><plain>8JobeAH, NewnhamJP, WilletKE, SlyP, ErvinMG, BachurskiC, et al Effects of antenatal endotoxin and glucocorticoids on the lungs of preterm lambs. American journal of obstetrics and gynecology. 2000;182(2):401–8. </plain></SENT>
<SENT sid="345" pm="."><plain>Epub 2000/02/29. .<?supplied-pmid 10694344?>10694344 </plain></SENT>
</text></ref><ref id="pone.0184938.ref009"><text><SENT sid="346" pm="."><plain>9VisscherM, NarendranV. The Ontogeny of Skin. Advances in wound care. 2014;3(4):291–303. </plain></SENT>
<SENT sid="347" pm="."><plain>Epub 2014/04/25. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/wound.2013.0467">10.1089/wound.2013.0467</ext-link> ; PubMed Central PMCID: PMCPmc3985523.<?supplied-pmid 24761361?>24761361 </plain></SENT>
</text></ref><ref id="pone.0184938.ref010"><text><SENT sid="348" pm="."><plain>10ProkschE, BrandnerJM, JensenJM. The skin: an indispensable barrier. Experimental dermatology. 2008;17(12):1063–72. </plain></SENT>
<SENT sid="349" pm="."><plain>Epub 2008/12/02. .<?supplied-pmid 19043850?>19043850 </plain></SENT>
</text></ref><ref id="pone.0184938.ref011"><text><SENT sid="350" pm="."><plain>11KempMW, SaitoM, KallapurSG, JobeAH, KeelanJA, LiS, et al Inflammation of the fetal ovine skin following in utero exposure to Ureaplasma parvum. Reproductive sciences (Thousand Oaks, Calif). 2011;18(11):1128–37. </plain></SENT>
<SENT sid="351" pm="."><plain>Epub 2011/10/28. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1933719111408114">10.1177/1933719111408114</ext-link> ; PubMed Central PMCID: PMCPmc3343146.<?supplied-pmid 22031190?>22031190 </plain></SENT>
</text></ref><ref id="pone.0184938.ref012"><text><SENT sid="352" pm="."><plain>12KempMW, SaitoM, NitsosI, JobeAH, KallapurSG, NewnhamJP. Exposure to in utero lipopolysaccharide induces inflammation in the fetal ovine skin. Reproductive sciences (Thousand Oaks, Calif). 2011;18(1):88–98. </plain></SENT>
<SENT sid="353" pm="."><plain>Epub 2010/10/07. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1933719110380470">10.1177/1933719110380470</ext-link> ; PubMed Central PMCID: PMCPmc3343071.<?supplied-pmid 20923949?>20923949 </plain></SENT>
</text></ref><ref id="pone.0184938.ref013"><text><SENT sid="354" pm="."><plain>13ZhangL, SaitoM, JobeA, KallapurSG, NewnhamJP, CoxT, et al Intra-amniotic administration of E coli lipopolysaccharides causes sustained inflammation of the fetal skin in sheep. Reproductive sciences (Thousand Oaks, Calif). 2012;19(11):1181–9. </plain></SENT>
<SENT sid="355" pm="."><plain>Epub 2012/05/19. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1933719112446079">10.1177/1933719112446079</ext-link> ; PubMed Central PMCID: PMCPmc4051405.<?supplied-pmid 22598485?>22598485 </plain></SENT>
</text></ref><ref id="pone.0184938.ref014"><text><SENT sid="356" pm="."><plain>14KempMW, KannanPS, SaitoM, NewnhamJP, CoxT, JobeAH, et al Selective exposure of the fetal lung and skin/amnion (but not gastro-intestinal tract) to LPS elicits acute systemic inflammation in fetal sheep. PloS one. 2013;8(5):e63355 Epub 2013/05/22. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0063355">10.1371/journal.pone.0063355</ext-link> ; PubMed Central PMCID: PMCPmc3656923.<?supplied-pmid 23691033?>23691033 </plain></SENT>
</text></ref><ref id="pone.0184938.ref015"><text><SENT sid="357" pm="."><plain>15WolfsTG, KallapurSG, PolglaseGR, PillowJJ, NitsosI, NewnhamJP, et al IL-1alpha mediated chorioamnionitis induces depletion of FoxP3+ cells and ileal inflammation in the ovine fetal gut. PloS one. 2011;6(3):e18355 Epub 2011/04/12. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0018355">10.1371/journal.pone.0018355</ext-link> ; PubMed Central PMCID: PMCPmc3066237.<?supplied-pmid 21479249?>21479249 </plain></SENT>
</text></ref><ref id="pone.0184938.ref016"><text><SENT sid="358" pm="."><plain>16KallapurSG, PresicceP, SenthamaraikannanP, AlvarezM, TarantalAF, MillerLM, et al Intra-amniotic IL-1beta induces fetal inflammation in rhesus monkeys and alters the regulatory T cell/IL-17 balance. Journal of immunology (Baltimore, Md: 1950). 2013;191(3):1102–9. </plain></SENT>
<SENT sid="359" pm="."><plain>Epub 2013/06/25. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.1300270">10.4049/jimmunol.1300270</ext-link> ; PubMed Central PMCID: PMCPmc3720768.<?supplied-pmid 23794628?>23794628 </plain></SENT>
</text></ref><ref id="pone.0184938.ref017"><text><SENT sid="360" pm="."><plain>17SenthamaraikannanP, PresicceP, RuedaCM, ManeenilG, SchmidtAF, MillerLA, et al Intra-amniotic Ureaplasma parvum-Induced Maternal and Fetal Inflammation and Immune Responses in Rhesus Macaques. The Journal of infectious diseases. 2016;214(10):1597–604. </plain></SENT>
<SENT sid="361" pm="."><plain>Epub 2016/10/30. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jiw408">10.1093/infdis/jiw408</ext-link> .<?supplied-pmid 27601620?>27601620 </plain></SENT>
</text></ref><ref id="pone.0184938.ref018"><text><SENT sid="362" pm="."><plain>18KomineM, RaoLS, FreedbergIM, SimonM, MilisavljevicV, BlumenbergM. Interleukin-1 induces transcription of keratin K6 in human epidermal keratinocytes. The Journal of investigative dermatology. 2001;116(2):330–8. </plain></SENT>
<SENT sid="363" pm="."><plain>Epub 2001/02/17. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1523-1747.2001.01249.x">10.1046/j.1523-1747.2001.01249.x</ext-link> .<?supplied-pmid 11180011?>11180011 </plain></SENT>
</text></ref><ref id="pone.0184938.ref019"><text><SENT sid="364" pm="."><plain>19GotschF, RomeroR, KusanovicJP, Mazaki-ToviS, PinelesBL, ErezO, et al The fetal inflammatory response syndrome. Clinical obstetrics and gynecology. 2007;50(3):652–83. </plain></SENT>
<SENT sid="365" pm="."><plain>Epub 2007/09/01. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/GRF.0b013e31811ebef6">10.1097/GRF.0b013e31811ebef6</ext-link> .<?supplied-pmid 17762416?>17762416 </plain></SENT>
</text></ref><ref id="pone.0184938.ref020"><text><SENT sid="366" pm="."><plain>20KallapurSG, NitsosI, MossTJ, PolglaseGR, PillowJJ, CheahFC, et al IL-1 mediates pulmonary and systemic inflammatory responses to chorioamnionitis induced by lipopolysaccharide. American journal of respiratory and critical care medicine. 2009;179(10):955–61. </plain></SENT>
<SENT sid="367" pm="."><plain>Epub 2009/02/24. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1164/rccm.200811-1728OC">10.1164/rccm.200811-1728OC</ext-link> ; PubMed Central PMCID: PMCPmc2684020.<?supplied-pmid 19234101?>19234101 </plain></SENT>
</text></ref><ref id="pone.0184938.ref021"><text><SENT sid="368" pm="."><plain>21KallapurSG, WilletKE, JobeAH, IkegamiM, BachurskiCJ. Intra-amniotic endotoxin: chorioamnionitis precedes lung maturation in preterm lambs. American journal of physiology Lung cellular and molecular physiology. 2001;280(3):L527–36. </plain></SENT>
<SENT sid="369" pm="."><plain>Epub 2001/02/13. .<?supplied-pmid 11159037?>11159037 </plain></SENT>
</text></ref><ref id="pone.0184938.ref022"><text><SENT sid="370" pm="."><plain>22KramerBW, MossTJ, WilletKE, NewnhamJP, SlyPD, KallapurSG, et al Dose and time response after intraamniotic endotoxin in preterm lambs. American journal of respiratory and critical care medicine. 2001;164(6):982–8. </plain></SENT>
<SENT sid="371" pm="."><plain>Epub 2001/10/06. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1164/ajrccm.164.6.2103061">10.1164/ajrccm.164.6.2103061</ext-link> .<?supplied-pmid 11587983?>11587983 </plain></SENT>
</text></ref><ref id="pone.0184938.ref023"><text><SENT sid="372" pm="."><plain>23EnkAH, AngeloniVL, UdeyMC, KatzSI. An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin. Journal of immunology (Baltimore, Md: 1950). 1993;150(9):3698–704. </plain></SENT>
<SENT sid="373" pm="."><plain>Epub 1993/05/01. .<?supplied-pmid 8473727?>8473727 </plain></SENT>
</text></ref><ref id="pone.0184938.ref024"><text><SENT sid="374" pm="."><plain>24TeruiT, HiraoT, SatoY, UesugiT, HondaM, IguchiM, et al An increased ratio of interleukin-1 receptor antagonist to interleukin-1alpha in inflammatory skin diseases. Experimental dermatology. 1998;7(6):327–34. </plain></SENT>
<SENT sid="375" pm="."><plain>Epub 1998/12/19. .<?supplied-pmid 9858135?>9858135 </plain></SENT>
</text></ref><ref id="pone.0184938.ref025"><text><SENT sid="376" pm="."><plain>25MizutaniH, BlackR, KupperTS. Human keratinocytes produce but do not process pro-interleukin-1 (IL-1) beta. </plain></SENT>
<SENT sid="377" pm="."><plain>Different strategies of IL-1 production and processing in monocytes and keratinocytes. The Journal of clinical investigation. 1991;87(3):1066–71. </plain></SENT>
<SENT sid="378" pm="."><plain>Epub 1991/03/01. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI115067">10.1172/JCI115067</ext-link> ; PubMed Central PMCID: PMCPmc329902.<?supplied-pmid 1999487?>1999487 </plain></SENT>
</text></ref><ref id="pone.0184938.ref026"><text><SENT sid="379" pm="."><plain>26KristensenM, DeleuranB, EedyDJ, FeldmannM, BreathnachSM, BrennanFM. Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin. </plain></SENT>
<SENT sid="380" pm="."><plain>Decreased expression of IRAP in psoriatic lesional epidermis. The British journal of dermatology. 1992;127(4):305–11. </plain></SENT>
<SENT sid="381" pm="."><plain>Epub 1992/10/01. .<?supplied-pmid 1419749?>1419749 </plain></SENT>
</text></ref><ref id="pone.0184938.ref027"><text><SENT sid="382" pm="."><plain>27GrovesRW, ShermanL, MizutaniH, DowerSK, KupperTS. Detection of interleukin-1 receptors in human epidermis. </plain></SENT>
<SENT sid="383" pm="."><plain>Induction of the type II receptor after organ culture and in psoriasis. The American journal of pathology. 1994;145(5):1048–56. </plain></SENT>
<SENT sid="384" pm="."><plain>Epub 1994/11/01. ; PubMed Central PMCID: PMCPmc1887420.<?supplied-pmid 7977638?>7977638 </plain></SENT>
</text></ref><ref id="pone.0184938.ref028"><text><SENT sid="385" pm="."><plain>28KempMW. Preterm birth, intrauterine infection, and fetal inflammation. Frontiers in immunology. 2014;5:574 Epub 2014/12/19. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2014.00574">10.3389/fimmu.2014.00574</ext-link> ; PubMed Central PMCID: PMCPmc4249583.<?supplied-pmid 25520716?>25520716 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
